$1 Million Awarded by DeGregorio Family Foundation to Improve Immunotherapy in Gastroesophageal Cancer
Summary
One immunotherapy that has shown tremendous results initially in blood cancers is Chimeric Antigen Receptor (CAR) T cell therapy. As they have done with novel CAR T cell therapies for blood cancers, they plan to translate this novel CAR T cell therapy to the clinic for GEA cancers with the goal of obtaining more durable responses for GEA patients and they march towards a cure.Co-PIs Dr. Smith, Aguirre and Klempner and collaborators all agree, "DeGregorio Family Foundation funding is transformative for our research at this stage. The commitment that the Foundation made will enable us to leverage our understanding of immunotherapy targets for gastric and esophageal cancers to accelerate the development of a novel cellular therapy for translation to the clinic to directly impact patients. ""We are honored to play a part in improving immunotherapy for gastroesophageal cancer patients," concluded Lynn DeGregorio, President and Founder of the DeGregorio Family Foundation, the only public foundation solely focused on funding research grants for both gastric and esophageal cancers.In 2020, gastric and esophageal cancers combined killed over 1.3 million people worldwide. The Institute focuses on training new generations of clinicians and scientists, disseminating innovative patient therapies and scientific discoveries around the world, and reducing the impact of cancer.The DeGregorio Family Foundation, founded in 2006 after a 10th member of the DeGregorio family died of stomach cancer, has raised more than $12 million to fund innovative research to cure gastric and esophageal cancers.
Funding
Review available funding amount, funding date, investors, and linked company information related to $1 Million Awarded by DeGregorio Family Foundation to Improve Immunotherapy in Gastroesophageal Cancer in the interactive ISVWorld profile.